## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.3% in lower entry zone (3.0-6.0%), top quartile (87th pct) cross-sectional ranking. Short-term MRS_5 (3.4%) confirms momentum alignment. Strong momentum (+2.7% 5-day acceleration). Outperforming sector by 6.6%. Caution: overbought RSI (71).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($80.92)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. University of Rochester Medical Center and GE HealthCare form seven-year Care Alliance to build advanced capabilities across system**
- Source: PharmiWeb.com | 20251203T170652 | Bullish | Relevance: 100%
- The University of Rochester Medical Center (URMC) and GE HealthCare have established a seven-year Care Alliance to enhance advanced capabilities across URMC's network in upstate New York. This collaboration focuses on creating a center of excellence in Imaging Sciences, introducing diagnostic tracer production for molecular imaging, and standardizing patient monitoring throughout the UR Medicine health system. The alliance aims to improve patient care access and efficiency through advanced imaging, precision medicine with radiopharmaceuticals, and standardized patient monitoring systems.

**2. GE HealthCare and Mayo Clinic unveil GEMINI-RT: A bold research collaboration in radiation therapy and advanced cancer care**
- Source: BioSpace | 20251204T101737 | Bullish | Relevance: 99%
-  GE HealthCare and Mayo Clinic have launched GEMINI-RT, an initiative to personalize radiation therapy through the integration of imaging, AI, and patient monitoring. This collaboration focuses on automation, predictive oncology, multi-modal therapies, and connected care to enhance clinical outcomes and streamline cancer treatment. The research aims to "twin the patient" by creating precise models of individual patient journeys, enabling tailored radiation therapy.

**3. GE HealthCare Technologies Inc. stock falls Thursday, underperforms market**
- Source: MarketWatch | 20251204T165600 | Neutral | Relevance: 99%
-  GE HealthCare Technologies Inc. (GEHC) saw its stock price decline by 1.28% to $82.52 on Thursday. This performance was in contrast to the broader market, as the S&P 500 Index rose, while the Dow Jones Industrial Average experienced a slight dip. The stock's fall ended a two-day winning streak for the company.

**4. GE HealthCare and Mayo Clinic unveil GEMINI-RT: A bold research collaboration in radiation therapy a**
- Source: PharmiWeb.com | 20251203T220744 | Bullish | Relevance: 99%
- GE HealthCare and Mayo Clinic have launched GEMINI-RT, a research collaboration aimed at transforming personalized radiation therapy and cancer care. The initiative integrates imaging, AI, and patient monitoring, focusing on four key pillars: automation, predictive oncology, multi-modal therapies, and outpatient monitoring. This collaboration seeks to enhance clinical outcomes, reduce clinician burnout, and accelerate innovation in radiation oncology.

**5. GE HealthCare (Nasdaq: GEHC), Mayo Clinic unveil GEMINI-RT to advance AI-guided radiation therapy**
- Source: Stock Titan | 20251203T130000 | Bullish | Relevance: 98%
- GE HealthCare and Mayo Clinic have launched GEMINI-RT, a research collaboration aimed at transforming personalized radiation therapy for cancer care using AI and advanced imaging. The initiative focuses on automation, predictive oncology, multi-modal therapies, and connected care to improve patient outcomes and reduce clinician burnout. This builds on a prior strategic radiology research alliance, leveraging Mayo Clinic's clinical expertise and GE HealthCare's technological innovation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Forward P/E 17.3x stretched relative to 9% growth. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.9B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 17.3 |
| Current P/E | 18.8 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.6% to 4.3% (+2.7% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 87th percentile. MRS_5 at 3.4% confirms short-term momentum alignment. Outperforming sector by 6.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.99), confirming momentum. RSI overbought at 71, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.30% (CS: 88) | Strong |
| RSI_14 | 71.3 | Overbought |
| MACD Histogram | 0.99 | Bullish |
| vs SMA20 | 1.112x | Above |
| vs SMA50 | 1.128x | Above |
| vs SMA200 | 1.144x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $85.46
- **Stop Loss:** $80.92 (5.3% risk)
- **Target:** $92.27 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 110
- **Position Value:** $9,400.60
- **Portfolio %:** 9.40%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*